Influence of genetic polymorphisms in UGT1A1, UGT1A7 and UGT1A9 on the pharmacokynetics of irinotecan, SN-38 and SN-38G;Influencia de los polimorfismos genéticos en UGT1A1, UGT1A7 y UGT1A9 sobre la farmacocinética de irinotecán, SN-38 y SN-38G

Farmacia Hospitalaria

Volumn 37, Issue 2, 2013, Pages 111-127

  Valenzuela Jimenez B ^a   Gonzalez Sales M ^b   Escudero Ortiz, V ^a   Martinez Navarro E ^a   Perez Ruixo C ^b   Rebollo Liceaga, J ^a   Gonzalez Manzano R ^a   Perez Ruixo J J ^c  

^a HOSPITAL QUIRÓN   (Spain)

^b Consulting Projects for Research ^*  (Spain)

^c AMGEN INC   (United States)

Author keywords

Genotype; Irinotecan; Isoform; NONMEM; Oncology; Pharmacokinetics; Polymorphism

Indexed keywords

BILIRUBIN; FIRTECAN; FIRTECAN GLUCURONIDE; IRINOTECAN; 7-ETHYL-10-HYDROXYCAMPTOTHECIN BETA-GLUCURONIDE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; GLUCURONIC ACID; GLUCURONOSYLTRANSFERASE; UDP-GLUCURONOSYLTRANSFERASE 1A9; UGT1A1 ENZYME; UGT1A7 PROTEIN, HUMAN;

ARTICLE; BODY SURFACE; CANCER PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; ADULT; AGED; ANALOGS AND DERIVATIVES; BLOOD; FEMALE; GENETICS; MALE; MIDDLE AGED; NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; FEMALE; GLUCURONATES; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; POLYMORPHISM, GENETIC;

EID: 84877728415     PISSN: 11306343     EISSN: 21718695     Source Type: Journal    
DOI: 10.7399/FH.2013.37.2.386     Document Type: Article

References (36)

1. Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: topote-can and irinotecan. Cancer Treat Rev. 1994;20:73-96.
2. Stupp R, Hegi ME, van den Bent MJ, Mason W P, Weller M, Mirimanoff RO, et al. Changing paradigms-an update on the multidisciplinary management of malignant glioma. Oncologist. 2006;11:165-80.
3. Ahn BJ, Choi MK, Park YS, Lee J, Park SH, Park JO, et al. Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration. Eur J Clin Pharmacol. 2010;66:1235-45.
4. Castro Núñez I, Echarri Arrieta E, Ferriols Lisart F, García Silva A, Martínez Cutillas J, Oliveras Arenas M, et al. Medicamentos citostá-ticos, 1 Edición Electrónica, 2006. ISBN: 84-689-5619-8. Disponi-ble en: http://www.sefh.es/libro/Wyeth/pdf/libro. pdf
5. Sobrero A, Ackland S, Clarke S, Pérez-Carrión R, Chiara S, Gapski J, et al. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metasta-tic colorectal cancer. Oncology. 2009;77:113-9.
6. Modest D P, Reinacher-Schick A, Stintzing S, Giessen C, Tannapfel A, Laubender R P, et al. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorec-tal cancer: a pooled analysis. Anticancer Drugs. 2012;23: 666-73.
7. Köhne CH, Hofheinz R, Mineur L, Letocha H, Greil R, Thaler J, et al. First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol. 2012;138:65-72.
8. Ficha técnica de Irinotecán. Agencia Española de Medicamentos y Productos Sanitarios. Disponible en: https://sinaem4.agemed.es/ consaem/especialidad.do?metodo=verFichaWordPdf&codigo=694 74&formato=pdf&formulario=FICHAS. Último acceso 20/05/2012.
9. Xie R, Mathijssen RHJ, Sparreboom A, Verweij J, Karlsson MO. Clini-cal pharmacokinetics of irinotecan and it s metabolites in relation with diarrhea. Clin Pharmacol Ther. 2002;72:265-75.
10. Cárdenas E, Gil I, Honorato J. Irinotecan. Rev Med Univ Navarra. 2002;46:49-55.
11. Klein CE, Gupta E, Reid JM, Atherton PJ, Sloan JA, Pitot HC, et al. Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide. Clin Pharmacol Ther. 2002;72:638-47.
12. Poujol S, Pinguet F, Ychou M, Abderrahim AG, Duffour J, Bressolle FM. A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecán and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen. Oncol Rep. 2007;18:1613-21.
13. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharma-cokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol. 2006;24:2237-44.
14. Innocenti F, Ratain MJ. Pharmacogenetics of irinotecan. Clinical perspectives on the utility of genotyping. Pharmacogenomics. 2006;7: 1211-21.
15. Poujol S, Bresolle F, Duffour J, Abderrahim AG, Astre C, Ychou M, et al. Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metas-tasic digestive cancer receiving FOLFIRI regimen. Cancer Chemother Pharmacol. 2006;58:292-305.
16. Thompson PA, Gupta M, Rosner GL, Yu A, Barrett J, Bomgaars L, et al. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from children s oncology group. Cancer Chemother Pharmacol. 2008;62:1027-37.
17. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res. 2001;7:2182-94.
18. Innocenti F, Vokes EE, Ratain MJ. Irinogenetics: What is the right star? J Clin Oncol. 2006;24:2221-4.
19. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst. 2007;99:1290-5.
20. Marcuello E, Altes A, Menoyo A, Del Río E, Gómez-Pardo M, Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer. 2004;91:678-82.
21. Massacesi C, Terrazzino S, Marcucci F, Rocchi Mb, Lippe P, Bisonni R, et al. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer. 2006; 106:1007-16.
22. Cecchin E, Innocenti F, D Andrea M, Corona G, De Mattia E, Biason P, et al. Predictive role of UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastasic col-orectal cancer patients treated with fluoracil, leucovoril, and irinote-can. J Clin Oncol. 2009;27:2457-65.
23. Zufía L, Aldaz A, Giráldez J. Separation methods for camptothecin and related compounds. J Chromatogr B. 2001;764:141-59.
24. Guidance for Industry: Bioanalytical Method Validation. U.S. Department of Health and Human Services. Food and Drug Administration Center for Drug Evaluation and Research (CDER). May 2001.
25. Validation of Analytical Methods: Methodology. ICH Topic Q2B. CPMP/ICH/281/95.
26. Villenueve L, Girard H, Fortier LC, Gagne J F, Guillemette C. Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuro nidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiri-dol anticancer drugs. J Pharmacol Exp Ther. 2003;307: 117-28.
27. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263-5.
28. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The structure of haplotype blocks in the human genome. Scien ce. 2002;296:2225-9.
29. Ahn JE, Karlsson MO, Dunne A, Ludden TM. Likelihood based approaches to handling data below te quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn. 2008;35:401-21.
30. Karlsson MO, Savic RM. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS Journal. 2009;11:558-69.
31. Mandema JW, Verotta D, Sheiner LB. Building population pharma-cokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biophar. 1992;20:511-28.
32. Brendel K, Comets E, Laffont C, Laveille C, Mentré F. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res. 2006;23:2036-49.
33. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 1994;54:3723-5.
34. Ramón-López A, Escudero-Ortiz V, Duart-Duart MJ, Pérez-Ruixo JJ, Valenzuela B. Population pharmacokinetics of gemcitabine applied to personalize the dosage used in cancer patients. Farm Hosp. 2012;36:194-206.
35. Palomaki GE, Bradley LA, Douglas M P, Kolor K, Dotson WD. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet Med. 2009;11:21-34.
36. Shitara K, Matsuo K, Takahari D, Yokota T, Inaba Y, Yamaura H, et al. Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. Eur J Cancer. 2009;45:1757-63.